Inhibiting Cancer-Causing Protein Could Prevent Scleroderma Fibrosis

Examining the autoimmune disease at the molecular level led researchers to a specific molecule that could be contributing to the disease progression in patients.

7:00 AM

Author | Kylie Urban

A protein known to play a role in cancer may also be increasing fibrosis in scleroderma patients.

Scleroderma, a rare, chronic autoimmune disease, is marked by hardening of the skin and internal organs. Symptoms often include pain, stiffness, fatigue and breathing difficulties.

LISTEN UP: Add the new Michigan Medicine News Break to your Alexa-enabled device, or subscribe to our daily audio updates on iTunes, Google Play and Stitcher.

"The disease creates excessive fibroblast activation that ultimately results in tissue damage and organ failure," says Amr Sawalha, M.D., a professor in the Division of Rheumatology at the University of Michigan.

In a new study, published in Proceedings of the National Academy of Sciences, Sawalha and his team examined scleroderma at the molecular level to better understand the fibrosis process.

When we suppressed EZH2, we found we could correct increased fibrosis and abnormal blood vessel function in scleroderma.
Amr Sawalha, M.D.

"We examined the molecule EZH2, which has been known to play a role in several types of cancer," Sawalha says. "This protein regulates gene expression, by affecting modifications that happen to DNA and other proteins attached to DNA, through a process called epigenetic regulation."

Sawalha and fellow researchers had previously identified a role for EZH2 in lupus, another autoimmune disease, flares.

"EZH2 is overexpressed in lupus T cells, which makes these white blood cells active in lupus patients," he says. "We then expanded our studies to scleroderma and specifically looked at the role of EZH2 in fibroblasts and endothelial cells in this disease."

Examining EZH2                            

The research team first isolated cells from scleroderma patients in collaboration with the Michigan Medicine Scleroderma Program. The program provides care for a large number of scleroderma patients at the University of Michigan. They then expanded their studies to animal models to further test findings identified in the human cells.  

"Both increased fibrosis and abnormal blood vessel function, or defective angiogenesis, are major aspects of pathology in this autoimmune disease," says Eliza Tsou, Ph.D., a research assistant professor at U-M and first author of the study. "We dissected the cells and found that increased levels of EZH2 were contributing to this disease process in scleroderma patients."

SEE ALSO: Systemic Scleroderma Treatments: Where Are We Now?

After identifying the molecule, the research team examined what happened in the cells when EZH2 was inhibited.

"When we suppressed EZH2, we found we could correct increased fibrosis and abnormal blood vessel function in scleroderma," Sawalha says.

Translating to the bedside

Because EZH2 is a molecule known to play a role in cancer patients, Sawalha says the ability to translate their laboratory work to patients may be easier.

"What is nice is that EZH2 inhibitors are already developed and in clinical trials in certain cancers," he says. "Therefore, our findings can be more readily translated to the bedside by repurposing already existing inhibitors for EZH2 to treat scleroderma."

MORE FROM MICHIGAN: Sign up for our weekly newsletter

As there are currently no effective treatment options for scleroderma, Sawalha notes that this type of research is important for future studies and trials.

"We will continue to research this disease at the molecular level and try to identify additional therapeutic targets for this patient population," he says.


More Articles About: Lab Report Basic Science and Laboratory Research Rheumatology All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories Muscle fiber microscopic scleroderma fibrosis
Health Lab
Tofacitinib shows promise in scleroderma patients, researchers are optimistic for next phase of study.
Phase I/II study of a rheumatoid arthritis drug used in systemic sclerosis shows signs of efficacy and RNA technology is instrumental in the discovery
Doctor wearing white glove pointing at the gout on side of foot
Health Lab
Gout Treatment Success Doubled by Combining Two Drugs, Study Finds
The findings are a promising step for a disease with limited treatment options.
Doctors trying to unclot a clogged artery
Health Lab
Subset of COVID-19 Patients Have Increased Bleeding Risk
A new potential biomarker raises concerns over the current standard for treating COVID-19 induced blood clots with high dose blood thinners.
graphic of pink orange skin tissue cell
Health Lab
National Research Effort Discovers Relationship Between Inflammation, Metabolism and Scleroderma Scarring
Study finds NAD+ break down leads to multi organ scarring, providing now a previously undiscovered pathogenic role of the enzyme CD38 in disease scarring.
grey transparent lungs seeing brachial branching
Health Lab
Protein Linked to Progressive Lung Scarring in Scleroderma Patients
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
Blood Cells
Health Lab
Impeding White Blood Cells in Antiphospholipid Syndrome Reduced Blood Clots
A new study examined APS at the cellular level and found that two drugs reduced development of blood clots in mice affected with the condition.